Article info

Original research
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Authors

  1. Correspondence to Dr Claire F Friedman, New York, New York, USA; friedmac{at}mskcc.org
View Full Text

Citation

Friedman CF, Spencer C, Cabanski CR, et al
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Publication history

  • Accepted December 4, 2021
  • First published January 24, 2022.
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.